Trials / Enrolling By Invitation
Enrolling By InvitationNCT07525089
Human Clinical Trial to Evaluate the Decolonization Efficacy of BM111 Against Carbapenem-Resistant Enterobacteriaceae (CRE) and Vancomycin-Resistant Enterococcus (VRE)
A Stratified, Randomized, Double-Blind, Placebo-Controlled Human Clinical Trial to Evaluate the Decolonization Efficacy of BM111 Against Carbapenem-Resistant Enterobacteriaceae (CRE) and Vancomycin-Resistant Enterococcus (VRE)
- Status
- Enrolling By Invitation
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- BioMe Inc. · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A clinical study to eliminate intestinal colonization in subjects harboring microorganisms resistant to carbapenem and vancomycin antibiotics, thereby treating infections caused by these microorganisms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | BM111 | A mixture of four intestinal microorganisms |
| DIETARY_SUPPLEMENT | Placebo | Placebo; Maltodextrin |
Timeline
- Start date
- 2026-03-23
- Primary completion
- 2026-10-30
- Completion
- 2027-02-20
- First posted
- 2026-04-13
- Last updated
- 2026-04-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07525089. Inclusion in this directory is not an endorsement.